斯普林沃克斯治疗公司的收益超过Q的估计,每股收益为0.54美元,收入为5973万美元. SpringWorks Therapeutics exceeded Q earnings estimates, with EPS at ($0.54) and revenue at $59.73M.
SpringWorks Therapeutics（纳斯达克股票代码：SWTX）的季度收益超出预期，每股收益为（$0.54）对（$1.12）的预期，营收为$59.73M对$34.42M。 SpringWorks Therapeutics (NASDAQ:SWTX) exceeds Q earnings estimates with EPS of ($0.54) vs. ($1.12) consensus, revenue $59.73M vs. $34.42M. 股价上1.48美元至37.41美元, HC Wainwright & Wedbush保持了74美元和75美元的目标价格的"买入"评级. Stock price up $1.48 to $37.41, HC Wainwright & Wedbush maintain "buy" ratings with $74 & $75 target prices. 公司的重点是罕见疾病和癌症,其第三阶段试验产品候选者OGSIVO(硝酸盐)用于脱菌肿瘤。 Company focuses on rare diseases, cancer, with its Phase III trial product candidate OGSIVEO (nirogacestat) for desmoid tumors.